- Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. *J Cereb Blood Flow Metab.* 2010;30:46–50.
- Sim-Selley LJ, Daunais JB, Porrino LJ, Childers SR. Mu and kappa1 opioidstimulated [³⁵S]guanylyl-5'-O-(gamma-thio)-triphosphate binding in cynomolgus monkey brain. *Neuroscience*. 1999;94:651–662.
- Seelig A, Gottschlich R, Devant RM. A method to determine the ability of drugs to diffuse through the blood-brain-barrier. *Proc Natl Acad Sci USA*. 1994;91:68–72.
- Wang D, Sun XC, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther. 2007;321:544–552.
- Zheng MQ, Nabulsi N, Kim SJ, et al. Synthesis and evaluation of ¹¹C-LY2795050 as a kappa-opioid receptor antagonist radiotracer for PET imaging. *J Nucl Med.* 2013;54:455–463.
- Rorick-Kehn LM, Witkin JM, Statnick MA, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. *Neuropharmacology*. 2014;77:131–144.
- Ragen BJ, Freeman SM, Laredo SA, Mendoza SP, Bales KL. mu and kappa opioid receptor distribution in the monogamous titi monkey (*Callicebus cupreus*): implications for social behavior and endocrine functioning. *Neuroscience*. 2015;290:421–434.
- Zheng MQ, Kim SJ, Holden D, et al. An improved antagonist radiotracer for the kappa-opioid receptor: synthesis and characterization of ¹¹C-LY2459989. J Nucl Med. 2014;55:1185–1191.
- Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. *Mol Imaging Biol.* 2003;5:363–375.

Erratum

In the article "Three-Dimensional Dosimetry for Radiation Safety Estimates from Intrathecal Administration," by Hesterman et al. (*J Nucl Med.* 2017;58:1672–1678), the absorbed doses given in Table 3 and the in-text references to these values from Table 3 are incorrect. The correct values appear in italics in the paragraphs as well as the table below. Despite these errors, there is no impact to the methods, statistical analysis, or conclusions. The authors regret the error.

In the abstract:

Simulation results were within 6% of OLINDA estimates for common organs. Absorbed dose estimates were highest (0.5–1.2 mGy/MBq) in the lumbar CSF space.

In the "Discussion: Clinical Data" section:

The lumbar CSF region experiences the highest exposure, with an absorbed dose per unit injected activity of approximately 1.2 ± 0.3 mGy/MBq for a 5-mL administered volume, with radiation dose decreasing along the spinal cord up to the brain. In the case of the 5-mL administration, the ratio of absorbed dose between lumbar and cervical CSF is approximately 6.0 and lumbar to brain tissue is about 32. A more uniform distribution of absorbed dose is observed with the 15-mL dose volume with lumbar–to–cervical and lumbar–to–brain tissue ratios of about 2.3 and 10.3, respectively. Additionally, the brain CSF, comprising largely the cisterns, and brain parenchyma doses are approximately 1.4 times higher in the 15-mL administered volume group than in the 5-mL group.

In the "Discussion: Biological Implications" section:

The current experimentally derived dosimetry after intrathecal administration indicates an absorbed dose per unit injected activity of up to *1.2* mGy/MBq in the lumbar spine (5-mL injection, n = 3 subjects). In this study, the administered activity of ^{99m}Tc was about 185 MBq, resulting in a total radiation dose of about 220 mGy (0.22 Gy).

TABLE 3

In Table 3:

Region	5 mL	15 mL
Brain	36.39 ± 16.25	51.38 ± 4.40
Right lung	3.50 ± 0.27	2.73 ± 0.32
Left lung	3.37 ± 0.25	2.63 ± 0.30
Liver	3.19 ± 0.33	2.09 ± 0.12
Kidneys	14.12 ± 1.27	9.85 ± 0.47
Stomach	3.23 ± 0.34	2.15 ± 0.12
Heart	2.01 ± 0.10	1.47 ± 0.11
Bladder	4.73 ± 1.53	6.69 ± 3.74
Cervical CSF	195.75 ± 88.44	231.41 ± 39.79
Thoracic CSF (upper)	353.68 ± 84.83	277.66 ± 83.72
Thoracic CSF (lower)	470.37 ± 34.79	365.47 ± 23.88
Lumbar CSF	1,174.70 ± 283.85	527.40 ± 98.70
Brain ventricle CSF	23.31 ± 10.39	32.83 ± 2.79
Entire body	3.32 ± 0.24	2.88 ± 0.10